Cargando…
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged, causing a global pandemic called COVID-19. Currently, there is no definitive treatment for this emerging disease. Global efforts resulted in developing multiple platforms of COVID-19 vaccines, but their efficacy in h...
Autores principales: | Farhangnia, Pooya, Dehrouyeh, Shiva, Safdarian, Amir Reza, Farahani, Soheila Vasheghani, Gorgani, Melika, Rezaei, Nima, Akbarpour, Mahzad, Delbandi, Ali-Akbar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021130/ https://www.ncbi.nlm.nih.gov/pubmed/35483235 http://dx.doi.org/10.1016/j.intimp.2022.108786 |
Ejemplares similares
-
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023) -
SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023) -
Death due to COVID‐19 in a patient with diabetes, epilepsy, and gout comorbidities
por: Safdarian, Amir Reza, et al.
Publicado: (2020) -
Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy
por: Aghamajidi, Azin, et al.
Publicado: (2022) -
Ellagic acid effects on disease severity, levels of cytokines and T-bet, RORγt, and GATA3 genes expression in multiple sclerosis patients: a multicentral-triple blind randomized clinical trial
por: Jafari Karegar, Sahar, et al.
Publicado: (2023)